Innovative Approaches to Psoriasis: Small Molecules Targeting Key Signaling Pathways.

IF 2.9 4区 医学 Q3 IMMUNOLOGY
Immunological Investigations Pub Date : 2025-05-01 Epub Date: 2025-01-17 DOI:10.1080/08820139.2025.2449960
Meeral Gosia, Gaurav Doshi, Siddhi Bagwe Parab, Angel Godad
{"title":"Innovative Approaches to Psoriasis: Small Molecules Targeting Key Signaling Pathways.","authors":"Meeral Gosia, Gaurav Doshi, Siddhi Bagwe Parab, Angel Godad","doi":"10.1080/08820139.2025.2449960","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Psoriasis (Pso) is a chronic, immune-mediated dermatological condition characterized by dysregulated inflammatory responses and the hyperproliferation of keratinocytes. Biologics, which target specific cytokines such as IL-17 and IL-23, have revolutionized the management by addressing key drivers of its pathophysiology. Despite their efficacy, biologics are not without limitations, including the need for intermittent administration and ongoing monitoring. In contrast, small molecules offer a promising alternative by selectively inhibiting key signaling pathways that modulate pro-inflammatory cytokines involved in the inflammatory cascade.</p><p><strong>Methods and results: </strong>This review suggests a new therapeutic strategy for Pso treatment, emphasizing the intricate relationships between small molecules and important signaling pathways involved in the pathophysiology of skin conditions. Improving treatment outcomes and reducing the side effects associated with conventional medicines, this review aims to better understand how tailored small-molecule inhibitors might efficiently control these pathways. This creative approach promotes the creation of individualized treatment plans that can greatly enhance the quality of life of patients with Psoby utilizing the knowledge gathered from recent developments in signaling pathway research.</p><p><strong>Conclusion: </strong>This review delves into the molecular mechanisms underlying Pso and explores how small molecules can be harnessed to enhance treatment outcomes, presenting a new paradigm for managing this chronic skin disorder.</p>","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"457-493"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820139.2025.2449960","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Psoriasis (Pso) is a chronic, immune-mediated dermatological condition characterized by dysregulated inflammatory responses and the hyperproliferation of keratinocytes. Biologics, which target specific cytokines such as IL-17 and IL-23, have revolutionized the management by addressing key drivers of its pathophysiology. Despite their efficacy, biologics are not without limitations, including the need for intermittent administration and ongoing monitoring. In contrast, small molecules offer a promising alternative by selectively inhibiting key signaling pathways that modulate pro-inflammatory cytokines involved in the inflammatory cascade.

Methods and results: This review suggests a new therapeutic strategy for Pso treatment, emphasizing the intricate relationships between small molecules and important signaling pathways involved in the pathophysiology of skin conditions. Improving treatment outcomes and reducing the side effects associated with conventional medicines, this review aims to better understand how tailored small-molecule inhibitors might efficiently control these pathways. This creative approach promotes the creation of individualized treatment plans that can greatly enhance the quality of life of patients with Psoby utilizing the knowledge gathered from recent developments in signaling pathway research.

Conclusion: This review delves into the molecular mechanisms underlying Pso and explores how small molecules can be harnessed to enhance treatment outcomes, presenting a new paradigm for managing this chronic skin disorder.

银屑病的创新方法:靶向关键信号通路的小分子。
背景:银屑病(Pso)是一种慢性、免疫介导的皮肤病,以炎症反应失调和角化细胞过度增殖为特征。针对特定细胞因子如IL-17和IL-23的生物制剂,通过解决其病理生理的关键驱动因素,已经彻底改变了管理。尽管具有疗效,但生物制剂并非没有局限性,包括需要间歇性给药和持续监测。相比之下,小分子通过选择性地抑制参与炎症级联反应的促炎细胞因子的关键信号通路,提供了一个有希望的替代方案。方法和结果:本文综述了一种新的治疗Pso的策略,强调了小分子和参与皮肤疾病病理生理的重要信号通路之间的复杂关系。改善治疗结果和减少与传统药物相关的副作用,本综述旨在更好地了解定制的小分子抑制剂如何有效地控制这些途径。这种创造性的方法促进了个性化治疗计划的创建,通过利用从信号通路研究的最新进展中收集的知识,可以极大地提高pso患者的生活质量。结论:本综述深入研究了Pso的分子机制,并探讨了如何利用小分子来提高治疗效果,为治疗这种慢性皮肤病提供了新的范例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Immunological Investigations
Immunological Investigations 医学-免疫学
CiteScore
5.50
自引率
7.10%
发文量
49
审稿时长
3 months
期刊介绍: Disseminating immunological developments on a worldwide basis, Immunological Investigations encompasses all facets of fundamental and applied immunology, including immunohematology and the study of allergies. This journal provides information presented in the form of original research articles and book reviews, giving a truly in-depth examination of the latest advances in molecular and cellular immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信